The ability of first generation TKIs, gefitinib and erlotinib, to effectively inhibit EGFR’s kinase activity were assessed in different wt-EGFR-positive cancer cells: prostate cancer cells PC3 and Du145, lung cancer cell A549, and breast cancer cell MDA-MB-231. This evidence concerns the gene EGFR and lung carcinoma.